Testosterone Therapy and Heart Safety: What Women Should Know
New research presented at a menopause conference raises fresh questions about cardiovascular safety in women using testosterone therapy, which is not FDA-approved for women.
Why Chronic Pain Can Surface or Worsen During Menopause
New reporting highlights a less-discussed menopause symptom cluster: persistent pain, often alongside sleep disruption, that can complicate daily life and be hard to separate from other conditions.
Menopause Care Is Getting More Attention, but Training Still Lags
Menopause is drawing more public and policy attention, but many clinicians still report limited training. Here’s what the evidence says about treatment, access, and uncertainty.
Trump’s new women’s health plan puts NIH in focus
A new executive order would create a women’s health division at NIH and a White House task force. The move raises hopes, but key details about funding and impact are still unclear.
When a Breast Lump Is Dismissed, Delayed Diagnosis Can Follow
A CBS News report highlights how a breast lump was initially minimized, underscoring why new breast changes deserve timely medical evaluation and follow-up.
Updated Menopause Guidance Reassesses Hormone Therapy
New guidance is putting hormone therapy back at the center of menopause care for some people with hot flashes and night sweats, while keeping safety limits and individual risk factors in view.
Trump order targets women’s health research, with menopause and aging in focus
A new White House order aims to expand federal attention to women’s health research. Here’s what it could mean, what science already shows, and what remains unclear.
New Research Suggests the Postmenopausal Ovary Is Not Idle
A new study adds to growing evidence that the ovary remains biologically active after menopause, with possible implications for hormone signaling, aging, and disease risk.
Why a mammogram may now flag more than breast cancer risk
Breast arterial calcification, or BAC, can show up on routine mammograms and may signal higher cardiovascular risk. The finding is promising, but not yet a stand-alone diagnosis or treatment trigger.
FDA review of abortion pill safety will stretch into 2027
The FDA says its safety review of mifepristone will continue into next year, keeping attention on a drug that is widely used for abortion and miscarriage care.